ERBB2 and neoplasm: In our study, the lapatinib + palbociclib combination treatment, targeting the HER2/AKT/mTOR signaling pathway and inhibiting the CDK4/6-Rb bypass pathway, significantly inhibited the survival of tumor cells and induced apoptosis.